Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 319

1.

Phase I trial of recombinant macrophage colony-stimulating factor and recombinant gamma-interferon: toxicity, monocytosis, and clinical effects.

Weiner LM, Li W, Holmes M, Catalano RB, Dovnarsky M, Padavic K, Alpaugh RK.

Cancer Res. 1994 Aug 1;54(15):4084-90.

2.

Phase I trial of recombinant human macrophage colony-stimulating factor administered by continuous intravenous infusion in patients with metastatic cancer.

Cole DJ, Sanda MG, Yang JC, Schwartzentruber DJ, Weber J, Ettinghausen SE, Pockaj BA, Kim HI, Levin RD, Pogrebniak HW, et al.

J Natl Cancer Inst. 1994 Jan 5;86(1):39-45.

PMID:
8271281
3.

Phase I evaluation of combination therapy with interleukin 2 and gamma-interferon.

Weiner LM, Padavic-Shaller K, Kitson J, Watts P, Krigel RL, Litwin S.

Cancer Res. 1991 Aug 1;51(15):3910-8.

4.

Phase I study of intravenously administered bacterially synthesized granulocyte-macrophage colony-stimulating factor and comparison with subcutaneous administration.

Lieschke GJ, Maher D, O'Connor M, Green M, Sheridan W, Rallings M, Bonnem E, Burgess AW, McGrath K, Fox RM, et al.

Cancer Res. 1990 Feb 1;50(3):606-14.

5.
6.

Phase I trial of recombinant macrophage colony-stimulating factor by rapid intravenous infusion in patients with cancer.

Redman BG, Flaherty L, Chou TH, Kraut M, Martino S, Simon M, Valdivieso M, Groves E.

J Immunother (1991). 1992 Jul;12(1):50-4.

PMID:
1637782
7.

Effects of bacterially synthesized recombinant human granulocyte-macrophage colony-stimulating factor in patients with advanced malignancy.

Lieschke GJ, Maher D, Cebon J, O'Connor M, Green M, Sheridan W, Boyd A, Rallings M, Bonnem E, Metcalf D, et al.

Ann Intern Med. 1989 Mar 1;110(5):357-64.

PMID:
2644886
8.

Clinical and immunological effects of granulocyte-macrophage colony-stimulating factor coadministered with interleukin 2: a phase IB study.

Schiller JH, Hank JA, Khorsand M, Storer B, Borchert A, Huseby-Moore K, Burns D, Wesly O, Albertini MR, Wilding G, Sondel PM.

Clin Cancer Res. 1996 Feb;2(2):319-30.

9.

A phase I trial of recombinant human macrophage colony-stimulating factor by rapid intravenous infusion in patients with refractory malignancy.

Zamkoff KW, Hudson J, Groves ES, Childs A, Konrad M, Rudolph AR.

J Immunother (1991). 1992 Feb;11(2):103-10.

PMID:
1571332
10.

Phase II trial of recombinant human macrophage colony-stimulating factor in metastatic soft tissue sarcoma.

Momin FA, Zalupski M, Heilbrun LK, Flaherty L, Fyfe G, Baker LH, Redman BG.

J Immunother Emphasis Tumor Immunol. 1994 Oct;16(3):224-8.

PMID:
7834122
11.

Clinical experience with CD64-directed immunotherapy. An overview.

Curnow RT.

Cancer Immunol Immunother. 1997 Nov-Dec;45(3-4):210-5. Review.

PMID:
9435876
12.
13.

Phase II trial of murine monoclonal antibody D612 combined with recombinant human monocyte colony-stimulating factor (rhM-CSF) in patients with metastatic gastrointestinal cancer.

Saleh MN, Khazaeli MB, Wheeler RH, Bucy RP, Liu T, Everson MP, Munn DH, Schlom J, LoBuglio AF.

Cancer Res. 1995 Oct 1;55(19):4339-46.

14.

Recombinant interleukin-2 in combination with recombinant interferon-gamma in patients with advanced malignancy: a phase 1 study.

Reddy SP, Harwood RM, Moore DF, Grimm EA, Murray JL, Vadhan-Raj S.

J Immunother. 1997 Jan;20(1):79-87.

PMID:
9101417
16.

Yeast-expressed granulocyte-macrophage colony-stimulating factor in cancer patients: a phase ib clinical study.

Herrmann F, Schulz G, Lindemann A, Meyenburg W, Oster W, Krumwieh D, Mertelsmann R.

Behring Inst Mitt. 1988 Aug;(83):107-18.

PMID:
2467645
17.

Phase Ib trial of granulocyte-macrophage colony-stimulating factor combined with murine monoclonal antibody R24 in patients with metastatic melanoma.

Chachoua A, Oratz R, Liebes L, Alter RS, Felice A, Peace D, Vilcek J, Blum RH.

J Immunother Emphasis Tumor Immunol. 1994 Aug;16(2):132-41.

PMID:
7804528
18.

Phase I study of continuous-infusion recombinant macrophage colony-stimulating factor in patients with metastatic melanoma.

Jakubowski AA, Bajorin DF, Templeton MA, Chapman PB, Cody BV, Thaler H, Tao Y, Filippa DA, Williams L, Sherman ML, Garnick MB, Houghton AN.

Clin Cancer Res. 1996 Feb;2(2):295-302.

20.

Supplemental Content

Support Center